Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents

In this paper analysis of anemia correction efficacy in multiple myeloma patients was shown. Patients (n = 68) treated with epoetin alfa (recombinant erythropoietin (rEPO)) 150 IU/kg subcutaneously three times per week (no more 20 weeks) were included in the study group. Patients who did not receive erythropoiesis-stimulating therapy were included in the control group (n = 31). Patients in both groups received at least 3 courses of chemotherapy and continued to receive anticancer treatment during follow-up. Baseline hemoglobin level was 5.3 g/dl – 10.0 g/dl. The increase in hemoglobin level to normal range (≥ 12.0 g/dl) during ≤ 20 weeks was considered as positive therapy response. Positive response rate was higher in patients received epoetin alfa comparing with control group (64.7 % and 25.8 %, respectively; p < 0.05). Transfusion dependence persisted in 6 from 19 study patients who received RBC transfusions along with rEPO therapy (31.6 %), whereas in 5 from 9 control group patients (55.6 %). In epoetin alfa group significant increase in reticulocytes count at 2–3 weeks of therapy
was revealed: from 27.3 × 109/l to 64.9 × 109/l (in patients with positive response) and from 13.3 × 109/l to 25.1 × 109/l (in patients without response). Changes in the reticulocytes count in the control group were not revealed. Thus in patients with positive response reticulocytes level significantly increased to 3 weeks of therapy compared with negative response patients (37.6 × 109/l versus 11.8 × 109/l, respectively; p < 0,05), it can be used as prognostic factors of rEPO response.

1. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома. Гематология: Новейший справочник / под общ. ред. К.М. Абдулкадырова. М.: Изд-во «Эксмо»; СПб.: Изд-во «Сова», 2004. С. 593–665.

2. Романенко Н.А., Бессмельцев С.С., Ругаль В.И. и др. Сочетание множественной миеломы и первичного миелофиброза с последующей трансформацией в острый миелоидный лейкоз (обзор и случай из практики). Мед академ журн 2011;11(1):46–57.

3. Вотякова О.М., Демина Е.А. Множественная миелома. Клиническая онкогематология: Руководство для врачей /под ред. М.А. Волковой. М.: Медицина, 2007. С. 847–873.

4. Рыжко В.В., Клодзинский А.А, Варламова Е.Ю. и др. «Несекретирующая» множественная миелома (обзор литературы и собственные наблюдения). Клин онкогематол 2010;3(3):270–7.

5. Steurer M., Wagner H., Gastel G. Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey. Wien Klin Wochenschr 2004;116(11–12):367–72.

6. Романенко Н.А., Абдулкадыров К.М. Патогенетическая коррекция анемии эритропоэзстимулирующими препаратами у больных лимфопролиферативными заболеваниями. Онкогематол 2011;3:39–49.

7. Шевченко Ю.Л., Заривчацкий М.Ф., Жибурт Е.Б. Трансфузионные осложнения и их профилактика.

8. В кн.: Шевченко Ю.Л., Шабалин В.Н., Заривчацкий М.Ф., Селиванов Е.А. (ред.) Руководство по общей и клинической трансфузиологии. СПб.: ООО «Издательство «Фолиант», 2003. С. 561–588.

9. Поспелова Т.И., Лямкина А.С. Уровень цитокинов (интерлейкина-1β, фактора некроза опухолей-α, интерферона-γ, интерлейкина-6) у больных лимфопролиферативными заболеваниями с анемическим синдромом. Анемия при лимфомах: научное издание. НГМУ. Новосибирск, 2008. С. 97–114.

10. Цветаева Н.В., Левина А.А., Мамукова Ю.И. Основы регуляции обмена железа. Клин онкогематол 2010;3(3):278–83.

11. Wang F.D., Zhou D.B., Li S.L. et al. Effect of recombinant human erythropoietin on hepcidin mRNA expression in patients with multiple myeloma. Zhongguo Shi Yan Xue Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011;19(2):390–4.

12. Baz R., Walker E., Choueiri T.K. et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol 2007;117(3):162–7.

13. Shehata N., Walker I., Meyer R. et al. The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological: a systematic review. Ann Hematol 2008;87(12):961–73.

14. Dammacco F., Castoldi G., Rodjer S. Efficacy of epoetin alfa in treatment of anemia of multiple myeloma. Br J Haematol 2001;113(1):172–9.

15. Mittelman M. The implications of anemia in multiple myeloma. Clin Lymphoma 2003;4(S1):23–9.

16. Yang S., Jun M., Hong-Li Z. et al. A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population. Int J Hematol 2008;88(2):139–44.

17. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома. Современный взгляд на проблему. Алматы, 2007. 480 с.

18. Henry D.H. Guidelines and recommendations for the management of anemia in patients with lymphoid malignancies. Drugs 2007;67(2):175–94.

19. Абдулкадыров К.М. Переливания эритроцитов. В кн. Клиническая гематология: Справочник. СПб.: Питер, 2006. С. 403–406.

20. Beguin Y. Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 1998;25 (3 Suppl 7):27–34.